Vemurafenib: the first drug approved for BRAF -mutant cancer
作者： Gideon Bollag , James Tsai , Jiazhong Zhang , Chao Zhang , Prabha Ibrahim
DOI: 10.1038/NRD3847
关键词:
摘要: … Before the discovery of the BRAF oncogene, CRAF was … CRAF led to a number of preclinical compounds 46 . Sorafenib (Nexavar; Bayer/Onyx), originally discovered as a CRAF inhibitor …
nature.com
sci-hub.se 
researchgate.net 参考文章(138)
Oliver Gautschi, Chantal Pauli, Klaus Strobel, Astrid Hirschmann, Gert Printzen, Stefan Aebi, Joachim Diebold, A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Journal of Thoracic Oncology. ,vol. 7, pp. e23- e24 ,(2012) , 10.1097/JTO.0B013E3182629903
E. W. Joseph, C. A. Pratilas, P. I. Poulikakos, M. Tadi, W. Wang, B. S. Taylor, E. Halilovic, Y. Persaud, F. Xing, A. Viale, J. Tsai, P. B. Chapman, G. Bollag, D. B. Solit, N. Rosen, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 14903- 14908 ,(2010) , 10.1073/PNAS.1008990107
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Malha Sahmi, Martin Lefrançois, Frank Sicheri, Marc Therrien, Thanashan Rajakulendran, A dimerization-dependent mechanism drives RAF catalytic activation Nature. ,vol. 461, pp. 542- 545 ,(2009) , 10.1038/NATURE08314
Harkanwal Halait, Kelli DeMartin, Sweta Shah, Stephen Soviero, Rachel Langland, Suzanne Cheng, Grantland Hillman, Lin Wu, H. Jeffrey Lawrence, Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma Diagnostic Molecular Pathology. ,vol. 21, pp. 1- 8 ,(2012) , 10.1097/PDM.0B013E31823B216F
Sug Hyung Lee, Jong Woo Lee, Young Hwa Soung, Hong Sug Kim, Won Sang Park, Su Young Kim, Jong Heun Lee, Jik Young Park, Yong Gu Cho, Chang Jae Kim, Suk Woo Nam, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo, BRAF and KRAS mutations in stomach cancer. Oncogene. ,vol. 22, pp. 6942- 6945 ,(2003) , 10.1038/SJ.ONC.1206749
C C Jiang, F Lai, K H Tay, A Croft, H Rizos, T M Becker, F Yang, H Liu, R F Thorne, P Hersey, X D Zhang, Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS Cell Death and Disease. ,vol. 1, pp. 1- 14 ,(2010) , 10.1038/CDDIS.2010.48
A Tannapfel, F Sommerer, M Benicke, A Katalinic, D Uhlmann, H Witzigmann, J Hauss, C Wittekind, Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut. ,vol. 52, pp. 706- 712 ,(2003) , 10.1136/GUT.52.5.706
Florian Sommerer, Michael Vieth, Annett Markwarth, Knut Röhrich, Susanne Vomschloß, Andrea May, Christian Ell, Manfred Stolte, Ulrich R Hengge, Christian Wittekind, Andrea Tannapfel, Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene. ,vol. 23, pp. 554- 558 ,(2004) , 10.1038/SJ.ONC.1207189
R. B. Corcoran, D. Dias-Santagata, K. Bergethon, A. J. Iafrate, J. Settleman, J. A. Engelman, BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation Science Signaling. ,vol. 3, ,(2010) , 10.1126/SCISIGNAL.2001148